EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms

Lianlian Du iD, Rebecca E Langhough, Bruce P Hermann, Erin M Jonaitis, Tobey J Betthauser, Leonardo A Rivera-Rivera, Karly A Cody, Nathaniel A Chin, Robert V Cadman, Kevin M Johnson, Aaron S Field, Sanjay Asthana und 3 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70831 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Lianlian Du und 14 weiteren Autor:innen. Beteiligte Einrichtung: Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: tau Proteins, Cognitive Dysfunction, Vascular Diseases, Amyloid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIA NIH HHS, Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Amyloid (A) and vascular (V) pathologies often co‐occur and progress over decades. We leveraged chronicity, defined as the years above a biomarker‐positivity threshold, to examine how the timing of A and V relates to cognitive decline. METHODS We modeled Clinical Dementia Rating–Sum of Boxes (CDR‐SB) trajectories in n = 558 participants with [C‐11] Pittsburgh compound B positron emission tomography (PET), magnetic resonance imaging–derived white matter hyperintensities (WMHs), and longitudinal CDR assessments. In n = 500 with MK6240 PET, we tested whether tau mediates A–V associations with CDR‐SB in a moderated mediation framework. RESULTS Whether biomarker “burden” was modeled as chronicity (A+years, V+years), or estimated amyloid and WMH at CDR visits, significant interactions showed a synergistic effect of WMHs and amyloid on accelerated CDR‐SB trajectories. Tau significantly mediated these associations. DISCUSSION Operationalizing chronicity clarifies how long individuals have exceeded A and V thresholds and improves clinical interpretability. WMH accumulation exacerbates amyloid‐related cognitive decline. Longitudinal tau imaging could further inform staging and intervention timing. Highlights Longer amyloid (A) and vascular disease (V) chronicity were associated with faster cognitive decline, emphasizing the importance of considering chronic exposure to these pathologies. Individuals with higher V burden experienced a steeper decline in cognition in the presence of A pathology, highlighting the interaction between V and neurodegenerative processes. Progression from early to mild dementia was faster with greater white matter hyperintensity chronicity, even when A duration was held constant, supporting the idea that V pathology amplifies the clinical impact of amyloid in Alzheimer's disease. Tau accumulation played a significant mediating role in linking A and V burden to cognitive decline, suggesting that tau pathology is a critical downstream factor in symptom progression. Person‐level chronicity estimates of A and V provide a more precise understanding of cognitive decline trajectories, offering insights for early intervention strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsCognitive DysfunctionVascular DiseasesAmyloidHumansMaleFemaleAgedPositron-Emission TomographyMagnetic Resonance ImagingDisease ProgressionWhite MatterLongitudinal StudiesBiomarkersMental Status and Dementia TestsAged, 80 and overAmyloid beta-Peptides

Stichwörter der Autor:innen

Clinical Dementia Ratingamyloidpreclinical Alzheimer's diseasewhite matter hyperintensities

Substanzen

tau ProteinsBiomarkersAmyloidAmyloid beta-Peptides

Autor:innen und Institutionen

  • Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
  • Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
  • Department of Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Department of Medical Physics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.

ORCID-Profile: Lianlian Du

Förderung

  • NIH HHS
  • NIA NIH HHS
  • Alzheimer's Association
  • National Institutes of Health

Zitieren

APA

Du, L., Langhough, R. E., Hermann, B. P., Jonaitis, E. M., Betthauser, T. J., Rivera-Rivera, L. A., Cody, K. A., Chin, N. A., Cadman, R. V., Johnson, K. M., Field, A. S., Asthana, S., Eisenmenger, L., Christian, B. T., & Johnson, S. C. (2025). Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70831

Vancouver

Du L, Langhough RE, Hermann BP, Jonaitis EM, Betthauser TJ, Rivera-Rivera LA, et al. Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70831

BibTeX
@article{Du2025,
  author = {Du, Lianlian and Langhough, Rebecca E and Hermann, Bruce P and Jonaitis, Erin M and Betthauser, Tobey J and Rivera-Rivera, Leonardo A and Cody, Karly A and Chin, Nathaniel A and Cadman, Robert V and Johnson, Kevin M and Field, Aaron S and Asthana, Sanjay and Eisenmenger, Laura and Christian, Bradley T and Johnson, Sterling C},
  title = {Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70831}
}
Kostenlos starten →